The inflammatory response in myocardial infarction

Cardiovascular Research

Volumn 53, Issue 1, 2002, Pages 31-47

  Frangogiannis, Nikolaos G ^a   Smith, C Wayne ^a   Entman, Mark L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Infarction; Infection inflammation; Ischemia; Reperfusion

Indexed keywords

CD18 ANTIGEN; CELL MARKER; CHEMOKINE; COMPLEMENT COMPONENT C5; FREE RADICAL; GROWTH FACTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE; SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

CELL METABOLISM; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME RELEASE; EXTRACELLULAR MATRIX; FIBROBLAST; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SCAR FORMATION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

NON-PROGRAMMATIC;

CELL ADHESION MOLECULES; CHEMOKINE CCL2; COMPLEMENT ACTIVATION; CYTOKINES; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MACROPHAGES; MAST CELLS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL INFILTRATION; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 0036136667     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00434-5     Document Type: Review

References (181)

1. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease
2. Cytokines and the microcirculation in ischemia and reperfusion
3. Role of inflammation following myocardial ischemia and reperfusion
4. Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain?
5. Oxygen-derived free radicals and postischemic myocardial dysfunction ('stunned myocardium')
6. Molecular and cellular mechanisms of myocardial stunning
7. Reduction of experimental myocardial infarct size by corticosteroid administration
8. Deleterious effects of methylprednisolone in patients with myocardial infarction
9. Mummification of the infarcted myocardium by high dose corticosteroids
10. Healing of myocardial infarcts in dogs. Effects of late reperfusion
11. Reperfusion in acute myocardial infarction: Effect of timing and modulating factors in experimental models
12. Effect of reperfusion on ventricular mass, topography, and function during healing of anterior infarction
13. The open-artery hypothesis
14. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury
15. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion
16. Comparison of antioxidant and nonantioxidant lipoxygenase inhibitors on neutrophil function. Implications for pathogenesis of myocardial reperfusion injury
17. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog
18. Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial salvage by anti-inflammatory drugs
19. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs
20. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase
21. The phlogistic role of C3 leukotactic fragment in myocardial infarcts of rats
22. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction
23. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion
24. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy
25. Complement gene expression by rabbit heart: Upregulation by ischemia and reperfusion
26. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury
27. Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion
28. Role of complement in in vitro and in vivo lung inflammatory reactions
29. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction
30. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
31. Complement inhibitors in myocardial ischemia/reperfusion injury
32. The complement system in myocardial ischaemia/reperfusion injury
33. Oxidative stress and cardiac disease
34. Status of myocardial antioxidants in ischemia-reperfusion injury
35. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury
36. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide
37. Role of superoxide in hemorrhagic shock-induced P-selectin expression
38. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils
39. H2O2 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-1 and NF-kappaB to the interleukin-8 promoter in endothelial and epithelial cells
40. Differential regulation of interleukin-8 and intercellular adhesion molecule-1 by H2O2 and tumor necrosis factor-alpha in endothelial and epithelial cells
41. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation
42. Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs
43. Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after 3 hours of occlusion followed by reperfusion
44. Therapy to reduce free radicals during early reperfusion does not limit the size of myocardial infarcts caused by 90 minutes of ischemia in dogs
45. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury
46. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice
47. Effects of superoxide dismutase on reperfusion arrhythmias and left ventricular function in patients undergoing thrombolysis for anterior wall acute myocardial infarction
48. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction
49. Reperfusion injury: A review of the pathophysiology, clinical manifestations and therapeutic options
50. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control
51. NF-kappaB activation: The I kappaB kinase revealed?
52. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats
53. Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts
54. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium
55. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction
56. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion
57. Mast cells in myocardial ischaemia and reperfusion
58. Histochemical and morphological characteristics of canine cardiac mast cells
59. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin
60. Mast cells as a source of multifunctional cytokines
61. Cardiac lymph flow in conscious dogs
62. Tumor necrosis factor in myocardial hypertrophy and ischaemia - An anti-apoptotic perspective
63. Endotoxin and ischemic preconditioning: TNF-alpha concentration and myocardial infarct development in rabbits
64. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction
65. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium
66. Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts
67. Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion
68. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury
69. The role of neutrophils in myocardial ischemia-reperfusion injury
70. The role of the neutrophil in myocardial ischemia and reperfusion
71. Role of neutrophils in myocardial ischemia and reperfusion
72. Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion
73. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow
74. Reperfusion injury: Experimental evidence and clinical implications
75. Leukocyte-endothelial cell interactions
76. Leukocyte-endothelial interactions and regulation of leukocyte migration
77. Selectins: Interpretors of cell-specific carbohydrate information during inflammation
78. Molecular mechanisms that control leukocyte extravasation: The selectins and the chemokines
79. Leukocyte trafficking mediated by selectin-carbohydrate interactions
80. Identification of an inducible endothelial-leukocyte adhesion molecule
81. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription
82. Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes
83. Molecular cloning and analysis of in vivo expression of murine P-selectin
84. Only simultaneous blocking of the L- and P-selectin completely inhibits neutrophil migration into mouse peritoneum
85. Function and regulation of the neutrophil MEL-14 antigen in vivo: Comparison with LFA-1 and MAC-1
86. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats
87. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice
88. Sequential contribution L- and P-selectin to leukocyte rolling in vivo
89. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice
90. Characterization of E-selectin-deficient mice: Demonstration of overlapping function of the endothelial selectins
91. Neutrophil rolling altered by inhibition of L-selectin shedding in vitro
92. L-Selectin shedding regulates leukocyte recruitment
93. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium
94. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury
95. Mechanisms that regulate the function of the selectins and their ligands
96. Glycolipid ligands for selectins support leukocyte tethering and rolling under physiologic flow conditions
97. Role of PSGL-1 binding to selectins in leukocyte recruitment
98. P-Selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin
99. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand
100. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats
101. Coronary endothelial P-selectin in pathogenesis of myocardial ischemia-reperfusion injury
102. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice
103. Integrins as dynamic regulators of vascular function
104. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro
105. Introduction: Functional polarity of motile neutrophils
106. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism
107. Monoclonal antibodies to leukocyte integrins CD11a/CD18 and CD11b/CD18 or intercellular adhesion molecule-1 inhibit chemoattractant-stimulated neutrophil transendothelial migration in vitro
108. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration
109. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice
110. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion
111. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function
112. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion
113. Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs
114. Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice
115. Chemokines
116. Chemokines and leukocyte traffic
117. Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes
118. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8
119. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo
120. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8
121. Role of platelet-activating factor in cardiovascular pathophysiology
122. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart
123. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury
124. Mechanisms of neutrophil-induced parenchymal cell injury
125. Adhesion molecules and inflammatory injury
126. Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/CD18-ICAM-1 adherence
127. Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion
128. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium
129. Molecular evidence for induction of intracellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart
130. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury
131. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions
132. Interleukin-6 (IL-6) as a mediator of stunned myocardium
133. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
134. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice
135. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction
136. Myocardial infarction and remodeling in mice: Effect of reperfusion
137. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium
138. Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration
139. Importance of monocytes/macrophages and fibroblasts for healing of micronecroses in porcine myocardium
140. Macrophage function
141. Properties and functions of interleukin-10
142. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes
143. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury
144. Abolished angiogenicity and tumorigenicity of burkitt lymphoma by interleukin-10
145. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb
146. Mast cells
147. Mast cell tryptase is a mitogen for cultured fibroblasts
148. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion
149. Identification of a committed precursor for the mast cell lineage
150. The c-kit receptor ligand functions as a mast cell chemoattractant
151. Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy
152. Mast cell expression of gelatinases A and B is regulated by kit-ligand and TGF-beta
153. The alpha-smooth muscle actin-positive cells in healing human myocardial scars
154. Evolution and clinical implications of the myofibroblast concept
155. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts
156. Infarct scar: A dynamic tissue
157. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart
158. Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb)
159. A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart
160. Collagen remodeling after myocardial infarction in the rat heart
161. Mechanisms of myofibroblast activity and phenotypic modulation
162. The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions
163. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
164. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction
165. Regulation of collagen degradation in the rat myocardium after infarction
166. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo
167. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
168. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction
169. Clinical applications of angiogenic growth factors and their inhibitors
170. Angiogenesis and angiogenesis inhibition: An overview
171. Mechanisms of angiogenesis and arteriogenesis
172. Molecular analysis of blood vessel formation and disease
173. Angiogenesis in the adult heart
174. Early expression of angiogenesis factors in acute myocardial ischemia and infarction
175. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis
176. Induction and suppression of Interferon-Inducible Protein (IP)-10 in reperfused myocardial infarcts may regulate angiogenesis
177. Induction of the synthesis of the C-X-C chemokine interferon-gamma-inducible protein-10 in experimental canine endotoxemia
178. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)
179. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
180. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
181. CD18 trials disappoint again